Fig. 6. ADG-2 prophylactic and S2P vaccination studies in mice.

N = 10 per group of BALB/c mice were treated with either ADG-2 or an isotype control antibody and then infected with PgCoV or SARS-CoV-2 MA10. PgCoV and MA10 infection (10⁴ p.f.u. per mouse) in the presence or absence of ADG-2 neutralizing antibody in BALB/c mice, n = 5 mice per group were collected at days 2 and 4 for titre and histological analysis. a, Weight loss. b, Lung viral titres at days 2 and 4 post infection. c, Lung discoloration scores. Another cohort of BALB/c mice (n = 10 mice per group) were vaccinated with SARS-CoV-2 S2P protein along with alum adjuvant and then challenged with PgCoV GD or mouse-adapted SARS-CoV-2 MA10 (10⁴ p.f.u. per mouse per virus), n = 5 mice per group were collected at days 2 and 4 for titre and histological analysis. d, Weight loss in PgCoV and SARS-CoV-2 MA10 challenged mice. e, Virus titres in the lung. f, Lung congestion scores of the challenged mice. We next evaluated PgCoV GD pathogenesis and DH1047 prophylaxis studies in K18-hACE2 mice, n = 15 mice per group. g, Weight loss following PgCoV GD challenge. h, PgCoV GD titres in the lung, nasal turbinates and brain (n = 5 per timepoint). i, Lung discoloration scores following PgCoV challenge. j, Percent survival following PgCoV GD challenge. k, Lung respiratory function (PenH) as measured by whole-body plethysmography. l–n, In another set of hACE2-K18 mice (n = 7 for the DH1047 group and n = 5 for the CH65 group), we demonstrated that the prophylactic administration of DH1047 protected against PgCoV weight loss (l), and reduces virus titre (m) and lung congestion (n). Data are mean ± s.d.